echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA grants AstraZeneca Tezepelumab orphan drug certification for the treatment of EoE

    FDA grants AstraZeneca Tezepelumab orphan drug certification for the treatment of EoE

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OrganizeSlowly

    AstraZeneca recently announced that the US FDA has granted Tezepelumab orphan drug certification for the treatment of a rare inflammatory disease, eosinophilic esophagitis (EoE)


    EoE is a rare chronic inflammatory disease involving a series of inflammatory cells, which can cause severe pain and dysphagia in patients


    Tezepelumab was jointly developed by AstraZeneca and Amgen.


    As early as July of this year, the US FDA has accepted the application for a biological product license (BLA) for the antibody drug tezepelumab for the treatment of severe asthma and granted priority review


    Tezepelumab BLA is based on positive data from the PATHFINDER clinical program, including positive results from the pivotal Phase 3 NAVIGATOR trial


    The NAVIGATOR trial is the first phase III trial that shows the therapeutic benefit of targeting TSLP for severe asthma


    In addition, in the subgroup of patients with a baseline eosinophil count of <300 cells/μl, the trial also reached the primary endpoint: compared with placebo+SoC, tezepelumab+SoC treatment made AAER statistically significant and Decrease of clinical significance


    According to estimates by AstraZeneca and Amgen, the US FDA is expected to make a decision on the priority review of Tezepelumab for American asthma patients in the first quarter of 2022


    At the same time, Tezepelumab is also undergoing regulatory review of asthma in the European Union and Japan


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.